Abstract:Tumor‐targeting bacteria have been developed as powerful anticancer agents. Salmonella typhimurium VNP20009, a representative tumor‐targeting strain, has been systemically administered as a single‐agent therapy at doses of 1 × 106 to 3 × 106 colony‐forming unit (cfu)/mouse, or in combination with other antitumor agents at doses of 1 × 104 to 2 × 105 cfu/mouse. Recently, we reported that oral delivery of VNP20009 at the dose of 1 × 109 cfu/mouse induced significant anticancer effects comparable to that induced by systemic administration of this strain at 1 × 104 cfu/mouse. To further address the efficacy and safety of oral administration of bacteria, here we performed a systemically comparative analysis of anticancer efficacy and toxicity of VNP20009 administered: (i) orally at a dose of 1 × 109 cfu/mouse (VNP9‐oral); (ii) intraperitoneally at a dose of 1 × 104 cfu/mouse (VNP4‐i.p.); or (iii) intraperitoneally at a dose of 1 × 106 cfu/mouse in tumor‐free and tumor‐bearing murine models. The results showed that VNP9‐oral, similar to VNP4‐i.p., induced significant tumor growth inhibition whereas VNP6‐i.p. induced better anticancer effect in the B16F10 melanoma model. Among three treatments, VNP9‐oral induced the mildest and reversible toxicity whereas VNP6‐i.p. resulted in the most serious and irreversible toxicities when compared to other two treatments. Moreover, the combination of VNP9‐oral with a low dose of chemotherapeutics produced comparable antitumor effects but displayed significantly reduced toxicity when compared to VNP6‐i.p. The findings demonstrated that oral administration, as a novel avenue in the application of bacteria, is highly safe and effective. Moreover, the present preclinical study should facilitate the optimization of bacterial therapies with improved anticancer efficacy and reduced adverse effects in future clinical trials. (Cancer Sci 2009; 100: 2437–2443)

Roles of VNP20009 in solid tumor therapy

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.

Proteomic Screening of Anaerobically Regulated Promoters from Salmonella and Its Antitumor Applications.

Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.

Oral Delivery of Tumor‐targeting Salmonella Exhibits Promising Therapeutic Efficacy and Low Toxicity

AttenuatedSalmonella VNP20009 Mutant(δhtra) is a Promising Candidate for Bacteria-Mediated Tumour Therapy in Hosts with TNFR1 Deficiency

Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model.

Modulation of Salmonella Tumor-Colonization and Intratumoral Anti-angiogenesis by Triptolide and Its Mechanism.

Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer

Inhibition of Expression of Vascular Endothelial Growth Factor and Its Receptors in Pulmonary Adenocarcinoma Cell by TNP-470 in Combination with Gemcitabine

Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models.

In Vivo Treatment of Tumors Using Host-Guest Conjugated Nanoparticles Functionalized with Doxorubicin and Therapeutic Gene Ptrail

Development of a Bacteria-Nanosapper for the Active Delivery of ZIF-8 Particles Containing Therapeutic Genes for Cancer Immune Therapy

Macrophage-mediated tumor-targeted delivery of engineered Salmonella typhimurium VNP20009 in anti-PD1 therapy against melanoma

Nanovaccines: An effective therapeutic approach for cancer therapy

Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger

Engineered bacteria breach tumor physical barriers to enhance radio-immunotherapy

Oncolytic bacteria VNP20009 expressing IFNβ inhibits melanoma progression by remodeling the tumor microenvironment

Synergistic antitumor activity of triple-regulated oncolytic adenovirus with VSTM1 and daunorubicin in leukemic cells

A New Oncolytic Adenoviral Vector Carrying Dual Tumour Suppressor Genes Shows Potent Anti-Tumour Effect